[
  {
    "ts": null,
    "headline": "Incyte (NASDAQ:INCY) Q3 Earnings: Leading The Immuno-Oncology Pack",
    "summary": "As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q3. Today, we are looking at immuno-oncology stocks, starting with Incyte (NASDAQ:INCY).",
    "url": "https://finnhub.io/api/news?id=bc3f7f1097fd32f8fff565d498c7486e6d438a05435f5b566efa333ae764c7de",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762831910,
      "headline": "Incyte (NASDAQ:INCY) Q3 Earnings: Leading The Immuno-Oncology Pack",
      "id": 137449306,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q3. Today, we are looking at immuno-oncology stocks, starting with Incyte (NASDAQ:INCY).",
      "url": "https://finnhub.io/api/news?id=bc3f7f1097fd32f8fff565d498c7486e6d438a05435f5b566efa333ae764c7de"
    }
  }
]